Payment overview · 2025
General Payments
$1,601.36
90 reported records · 21 companies
Healthcare provider profile · identity verified
David C Crabtree, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · SPRINGFIELD, IL · NPI 1487605291
Verified facts
What the public records show
CMS Open Payments records show David C Crabtree, M.D. received $1,601.36 in general payments during 2025 across 90 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gammaked, Nucala, Trelegy Ellipta, Xhance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Privigen by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 451 claims for Trelegy Ellipta by this doctor in 2024.
Kedrion Biopharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAKED as an associated drug or biological on 761 records involving 541 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gammaked by this doctor in 2024.
Optinose US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xhance as an associated drug or biological on 10863 records involving 5058 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xhance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
Paratek Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XHANCE as an associated drug or biological on 2604 records involving 2200 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xhance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $381.62 | 23.8% | 12 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $236.24 | 14.8% | 23 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $199.51 | 12.5% | 14 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $109.14 | 6.8% | 6 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $98.19 | 6.1% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $93.79 | 5.9% | 4 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $92.04 | 5.8% | 5 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $47.64 | 3.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.49 | 2.6% | 2 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $41.35 | 2.6% | 2 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $40.66 | 2.5% | 2 | 2025 |
| Kedrion Biopharma, Inc. | Unresolved — no canonical attribution shown | $37.98 | 2.4% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $33.16 | 2.1% | 2 | 2025 |
| GC Biopharma USA, Inc. | Unresolved — no canonical attribution shown | $24.39 | 1.5% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $24.28 | 1.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.62 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.01 | 1.1% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.15 | 1.1% | 1 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.83 | 1.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.77 | 1.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.50 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,601.36 | 90 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $258.22 | 4 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $236.24 | 23 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $191.23 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $182.92 | 13 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $173.20 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $152.72 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $131.35 | 7 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $109.14 | 6 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $72.59 | 4 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $70.35 | 5 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Optinose US, Inc., Paratek Pharmaceuticals, Inc. | $57.81 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $47.64 | 3 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $46.33 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $42.60 | 4 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological | Octapharma USA, Inc. | $41.35 | 2 | 2025 |
Source payment records
|
|||||
| Albuked Normalized: albuked |
Biological | Kedrion Biopharma, Inc. | $37.98 | 2 | 2025 |
Source payment records
|
|||||
| GAMMAKED Normalized: gammaked |
Biological | Kedrion Biopharma, Inc. | $37.98 | 2 | 2025 |
Source payment records
|
|||||
| KEDRAB Normalized: kedrab |
Biological | Kedrion Biopharma, Inc. | $37.98 | 2 | 2025 |
Source payment records
|
|||||
| KOATE Normalized: koate |
Biological | Kedrion Biopharma, Inc. | $37.98 | 2 | 2025 |
Source payment records
|
|||||
| RhoGAM Ultra-Filtered PLUS Normalized: rhogam ultra filtered plus |
Biological | Kedrion Biopharma, Inc. | $37.98 | 2 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $28.79 | 1 | 2025 |
Source payment records
|
|||||
| ALYGLO Normalized: alyglo |
Drug | GC Biopharma USA, Inc. | $24.39 | 1 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| Haegarda Normalized: haegarda |
Biological | CSL Behring | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| CUVITRU Normalized: cuvitru |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| DAWNZERA Normalized: dawnzera |
Drug | Ionis Pharmaceuticals, Inc. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| Rhapsido Normalized: rhapsido |
Drug | Novartis Pharmaceuticals Corporation | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GAMMAKED gammaked |
2025 | Gammaked | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUCALA nucala |
2025 | Nucala | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 451 | exact normalized | Medicare Part D |
| XHANCE xhance |
2025 | Xhance | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
451 | 85 |
| Kedrion Biopharma, Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAKED open payments reported associated product |
CMS Open Payments — General Payments 761 supporting records · 541 recipient NPIs · example record 1206766586 |
Gammaked · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Optinose US, Inc. Exact reporting entity; no affiliate inference |
2025 | Xhance open payments reported associated product |
CMS Open Payments — General Payments 10863 supporting records · 5058 recipient NPIs · example record 1163252000 |
Xhance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Paratek Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | XHANCE open payments reported associated product |
CMS Open Payments — General Payments 2604 supporting records · 2200 recipient NPIs · example record 1181734372 |
Xhance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 451 | 85 |
| Prednisone | Prednisone | 448 | 191 |
| Montelukast Sodium | Montelukast Sodium | 344 | 100 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 271 | 110 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 173 | 41 |
| Doxycycline Hyclate | Doxycycline Hyclate | 157 | 106 |
| Fluticasone Propionate | Fluticasone Propionate | 143 | 55 |
| Azithromycin | Azithromycin | 139 | 84 |
| Omeprazole | Omeprazole | 107 | 29 |
| Famotidine | Famotidine | 103 | 32 |
| Azelastine Hcl | Azelastine Hcl | 96 | 35 |
| Theophylline Er | Theophylline Anhydrous | 83 | 15 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 75 | 25 |
| Breo Ellipta | Fluticasone/Vilanterol | 55 | 13 |
| Dulera | Mometasone/Formoterol | 53 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 43 |
| Levofloxacin | Levofloxacin | 47 | 35 |
| Alprazolam | Alprazolam | 45 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 45 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 32 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 32 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 31 | suppressed |
| Nystatin | Nystatin | 31 | 20 |
| Eliquis | Apixaban | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | 12 |
| Breyna | Budesonide/Formoterol Fumarate | 28 | 11 |
| Qvar Redihaler | Beclomethasone Dipropionate | 28 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 13 |
| Furosemide | Furosemide | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 16 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Epinephrine | Epinephrine | 15 | 14 |
| Fluconazole | Fluconazole | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | suppressed |
| Dayvigo | Lemborexant | 13 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 13 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Nucala | Mepolizumab | 11 | suppressed |
| Xhance | Fluticasone Propionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,601.36 · 90 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ALYGLO, AREXVY, Albuked, Arikayce, BREZTRI, Brinsupri, CUVITRU, DAWNZERA, DUPIXENT, FASENRA, GAMMAKED, GLASSIA, HYQVIA, Haegarda, Hizentra, KEDRAB, KOATE, NUCALA, NURTEC ODT, NUZYRA, OCTAGAM IMMUNE GLOBULIN (HUMAN), OFEV, Ohtuvayre, PAXLOVID, Rhapsido, RhoGAM Ultra-Filtered PLUS, Sunosi, TEZSPIRE, TRELEGY ELLIPTA, XHANCE, Xembify, YUPELRI | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gammaked play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error